BIO-Europe Spring 2017
The process of bringing a pharmaceutical drug to market once a lead compound has been identified: from drug discovery, funding, clinical trials, FDA approvals, and partnerships
Barcelona biotech companies shine light on regional entrepreneurship
Investors are always on the lookout for innovative biotech startups, and the Catalonia, Spain biopharma cluster has plenty to offer in the way of innovation from among its member companies....
Increase the value of your asset: Think with the end in mind
Developing a drug is a very long journey, therefore it is critical to define the destination upfront. The Target Product Profile is like a postcard of your desired destination. It informs the data...
What’s the deal with Immuno-oncology partnering?
Insight wanted to get the lay of the I/O landscape, so who better to speak with than Jeff Bockman, Vice President of Defined Health. Not only was Jeff kind enough to share his insights with us,...
Barcelona’s GP Pharm considers partnering key to international expansion
Barcelona is an attractive location for business and trade, and has experienced a revival in the biopharma sector in recent years with the outsourcing of innovation from pharma companies to...
Welcome to Barcelona—one of the most vibrant life sciences hubs in Europe
Guest article by BIOCAT, the Bioregion of Catalonia After the great success of previous editions (2010 and 2013), the Bioregion of Catalonia is again hosting BIO-Europe Spring® 2017 (March 20–22),...
BIO-Europe Spring® 2016: BeyondSpring Pharmaceuticals outlines Plinabulin plans
BIO-Europe Spring® 2016: Motif's CEO on business leap from discovery to clinical-stage biotech
Dr. Graham Lumsden, CEO of London-based biotech Motif Bio, a company focused on the development of therapeutics for infectious diseases, talks with Mike Ward, global director of content for Informa Ph
BIO-Europe Spring® 2016: Purdue CEO outlines plans for growth away from opioid market
During the 2016 BIO-Europe Spring® partnering meeting in Stockholm, Sweden, Mark Timney, president and CEO of Purdue Pharma, caught up with Mike Ward, global director of content for Informa Pharma Int
BIO-Europe® 2016: Immunotherapies: Partnership models driving cures
While we have seen new immunotherapies enter the market and there are many exciting products in development; we have also seen recent setbacks. The field is risky and partnerships among biotechs, phar
Partnering in the Pharma World: BIO-Europe® and industry trends 2012-2015
BIO-Europe Spring® 2016: How to get Takeda Ventures to notice your startup
Dr. Ilan Zipkin, senior investment director at Takeda Ventures, talks with Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about what the venture capital fi
Drug pricing scandal rocks the USA but does not shake European systems
Single-payer European healthcare systems may hold a stronger position to defend the value of drugs than the fragmented payer system in the United States, according to a blue-ribbon panel of...
BIO-Europe Spring® 2016: What alliance opportunities excite Genentech?
Dr. Thomas Zioncheck, senior director of Genentech Partnering (a unit of Roche subsidiary Genentech Inc.), speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights po
BIO-Europe Spring® 2016: AZ BioVenture Hub CEO says aim is an innovative ecosystem
AstraZeneca’s BioVentureHub CEO Magnus Björsne tells Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about the exchange's intention to generate a climate of
Biotechs scramble as public markets dry up, but can private equity help?
Does the slump in the IPO boom create a bigger pool of private capital to invest in drug development, or do emerging companies have their backs to the wall? Professional investors hold mixed...
BIO-Europe® 2016 recap from day one
It was the best of times, it was the worst of times. This was the biotech industry in 2016. While this year marked yet another blockbuster year for dealmaking where larger pharma companies scooped...
BIO-Europe® 2016- Value and the pricing of innovation
Balancing the cost of innovation and ensuring access to high-quality, effective medical treatment continues to be a challenge for all modern healthcare systems. Significant shifts in global and local
Steps for choosing the right development partner
Guest post by Laura Marquis, Vice President and Global Head, Emerging Biopharma, QuintilesIMS™ As I prepare for BIO-Europe® in Cologne, I’m excited by the tremendous opportunities for emerging...
Covance: Expedited drug development with a new programmatic model
Drug development is undergoing a major transformation in order to align with the new norma—replacing a transactional or just-in-time approach with strategic programmatic outsourcing. This new,...
Aging R&D takes center stage at BIO-Europe®
Guest post by John Carroll, Co-Founder and Editor of Endpoints Last spring I was fascinated to read a story about seniors lobbying to get into a study that was being created to examine the...